PE20251285A1 - Composiciones farmaceuticas de glp1 - Google Patents

Composiciones farmaceuticas de glp1

Info

Publication number
PE20251285A1
PE20251285A1 PE2024002463A PE2024002463A PE20251285A1 PE 20251285 A1 PE20251285 A1 PE 20251285A1 PE 2024002463 A PE2024002463 A PE 2024002463A PE 2024002463 A PE2024002463 A PE 2024002463A PE 20251285 A1 PE20251285 A1 PE 20251285A1
Authority
PE
Peru
Prior art keywords
fluoro
glp1
pharmaceutical compositions
oxoimi
methylindazol
Prior art date
Application number
PE2024002463A
Other languages
English (en)
Spanish (es)
Inventor
Lee Joseph Burns
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20251285A1 publication Critical patent/PE20251285A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2024002463A 2022-05-11 2023-05-10 Composiciones farmaceuticas de glp1 PE20251285A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PE20251285A1 true PE20251285A1 (es) 2025-05-14

Family

ID=86732348

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002463A PE20251285A1 (es) 2022-05-11 2023-05-10 Composiciones farmaceuticas de glp1

Country Status (16)

Country Link
US (1) US20250302809A1 (enExample)
EP (1) EP4522129A1 (enExample)
JP (1) JP7767651B2 (enExample)
KR (1) KR20250002778A (enExample)
CN (1) CN119173255A (enExample)
AR (1) AR129296A1 (enExample)
AU (1) AU2023269995A1 (enExample)
CA (1) CA3253043A1 (enExample)
CL (1) CL2024003392A1 (enExample)
CO (1) CO2024015285A2 (enExample)
DO (1) DOP2024000232A (enExample)
IL (1) IL316629A (enExample)
MX (1) MX2024013839A (enExample)
PE (1) PE20251285A1 (enExample)
TW (2) TW202508581A (enExample)
WO (1) WO2023220109A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025108361A1 (zh) * 2023-11-21 2025-05-30 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002064132A2 (en) * 2001-01-18 2002-08-22 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CN101511184A (zh) * 2006-09-08 2009-08-19 默克公司 用于口服给药cgrp拮抗剂的液体药物制剂
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
CN120284862A (zh) * 2018-12-07 2025-07-11 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
UY38696A (es) * 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
KR20230066379A (ko) * 2020-09-09 2023-05-15 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 제형
US20250325525A1 (en) * 2022-05-11 2025-10-23 Eli Lilly And Company Glp1 tablet compositions

Also Published As

Publication number Publication date
TWI867526B (zh) 2024-12-21
MX2024013839A (es) 2024-12-06
KR20250002778A (ko) 2025-01-07
WO2023220109A1 (en) 2023-11-16
EP4522129A1 (en) 2025-03-19
TW202410894A (zh) 2024-03-16
CA3253043A1 (en) 2023-11-16
CO2024015285A2 (es) 2024-11-28
TW202508581A (zh) 2025-03-01
AR129296A1 (es) 2024-08-07
CN119173255A (zh) 2024-12-20
IL316629A (en) 2024-12-01
CL2024003392A1 (es) 2025-03-14
AU2023269995A1 (en) 2024-11-14
JP2025515706A (ja) 2025-05-20
JP7767651B2 (ja) 2025-11-11
US20250302809A1 (en) 2025-10-02
DOP2024000232A (es) 2024-12-30

Similar Documents

Publication Publication Date Title
PE20251285A1 (es) Composiciones farmaceuticas de glp1
JP2023156479A (ja) ジペプチジルペプチダーゼ1阻害剤としての(2s)-n-[(1s)-1-シアノ-2-フェニルエチル]-1,4-オキサゼパン-2-カルボキサミド
US7402603B2 (en) Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
PE20250009A1 (es) Composiciones de comprimidos de glp1
AR035074A1 (es) Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticas
HUE031441T2 (hu) 6-benzilfenil-2-kéntetrahidropirán-3,4,5-triolszármazékokat tartalmazó kombinációk mint nátrium-glükóz ko-transzporter 1 és 2 inhibitorai diabéteszes páciensekben való alkalmazásra
JP2007505142A (ja) 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
PE20080522A1 (es) Derivados de indol como inhibidores de los transportadores de glucosa dependientes de sodio (sglt)
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
CA2527368A1 (en) Pharmaceutical composition
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
PE20231847A1 (es) Compuestos fosfolipidos y usos de los mismos
AR064636A1 (es) Nuevos compuestos 621
EP3291811B1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
PE66998A1 (es) Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2
TW202015676A (zh) 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途
WO2009099172A1 (ja) 医薬
CH683068A5 (fr) Compositions pharmaceutiques contenant des dérivés de furanne.
PE20060533A1 (es) Derivados de dicetopiperazina como antagonistas del receptor de oxitocina
RU2013130801A (ru) Фармацевтическая композиция для лечения заболеваний суставов и костных тканей
EP1079863A1 (en) Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
RU2025121729A (ru) Фармацевтическая композиция агониста гпп для перорального введения
CO5750042A1 (es) Composicion farmaceutica que contiene zofenopril y hctz para el tratamiento de la hipertension